Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC Patients

被引：0
|
作者：
Shen, B. [1 ,2 ]
Pan, B. [1 ,2 ]
Wu, Y. [1 ,2 ]
Shi, L. [1 ,2 ]
Gao, J. [1 ,2 ]
Du, X. [1 ,2 ]
Feng, J. [1 ,2 ]
机构：
[1] Nanjing Med Univ, Affiliated Canc Hosp, Nanjing, Peoples R China
[2] Jiangsu Canc Hosp, Nanjing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Elderly NSCLC; Tislelizumab; First-line;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.06-03
引用
收藏
页码：S317 / S318
页数：2
相关论文
共 50 条
  • [1] Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced NSCLC in Patients aged ≥ 70
    Shen, B.
    Pan, B.
    Wu, Y.
    Shi, L.
    Gao, J.
    Feng, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S379 - S379
  • [2] First-line HDACi plus tislelizumab combined with chemotherapy in advanced NSCLC
    Wang, Lijie
    Gao, Ming
    Yang, Wenyu
    Wang, Chunyu
    Wang, Ting
    Jing, Fangfang
    Ma, Junxun
    Zhang, Fan
    Tao, Haitao
    Hu, Yi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC
    Lu, S.
    Yu, Y.
    Yu, X.
    Hu, Y.
    Ma, Z.
    Li, X.
    Zhuang, W.
    Liu, Y.
    Li, W.
    Cui, J.
    Wang, D.
    Liao, W.
    Wang, M.
    Zhou, J.
    Wang, Z.
    Sun, Y.
    Gao, J.
    Bao, Y.
    Liang, L.
    Wang, J.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S816 - S817
  • [4] Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer (SQ NSCLC)
    Wang, J.
    Lu, S.
    Hu, C.
    Sun, Y.
    Yang, K.
    Chen, M.
    Zhao, J.
    Yu, G.
    Zhou, X.
    Feng, G.
    Pan, Y.
    Yu, Y.
    Zhang, J.
    Liang, L.
    Lin, X.
    Wu, X.
    Cui, J.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S817 - S817
  • [5] Tislelizumab plus chemotherapy as first-line treatment for lung cancer in Chinese patients
    Wang, Z.
    Zhao, J.
    Ma, Z.
    Cui, J.
    Shu, Y.
    Liu, Z.
    Cheng, Y.
    Leaw, S.
    Wu, Y.
    Ma, Y.
    Tan, W.
    Wang, J.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1444 - S1444
  • [6] RATIONALE-307: Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65.
    Wang, Jie
    Lu, Shun
    Yu, Xinmin
    Hu, Yanping
    Sun, Yuping
    Wang, Zhijie
    Zhao, Jun
    Yu, Yan
    Hu, Chunhong
    Yang, Kunyu
    Feng, Guosheng
    Ying, Kejing
    Zhuang, Wu
    Zhou, Jianying
    Wu, Jingxun
    Leaw, Shiang Jiin
    Zhang, Jing
    Lin, Xiao
    Yang, Nong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Tislelizumab Combined With Chemotherapy as First-Line Treatment in Chinese Patients With Advanced Lung Cancer
    Zhao, J.
    Wang, Z.
    Ma, Z.
    Cui, J.
    Shu, Y.
    Liu, Z.
    Cheng, Y.
    Leaw, S.
    Li, J.
    Xia, F.
    Wang, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S540 - S540
  • [8] Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
    Lu, Shun
    Wang, Jie
    Yu, Yan
    Yu, Xinmin
    Hu, Yanping
    Ai, Xinghao
    Ma, Zhiyong
    Li, Xingya
    Zhuang, Wu
    Liu, Yunpeng
    Li, Weidong
    Cui, Jiuwei
    Wang, Dong
    Liao, Wangjun
    Zhou, Jianying
    Wang, Zhehai
    Sun, Yuping
    Qiu, Xiusong
    Gao, Jie
    Bao, Yuanyuan
    Liang, Liang
    Wang, Mengzhao
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1512 - 1522
  • [9] Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
    Lu, Shijie
    Lou, Yake
    Rong, Yi
    Huang, Zirui
    Lin, Xiaodan
    Chen, Junying
    Luo, Kongjia
    [J]. CLINICAL DRUG INVESTIGATION, 2023, 43 (08) : 643 - 652
  • [10] Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
    Shijie Lu
    Yake Lou
    Yi Rong
    Zirui Huang
    Xiaodan Lin
    Junying Chen
    Kongjia Luo
    [J]. Clinical Drug Investigation, 2023, 43 : 643 - 652
12345